HTA and Payer Activity: Oncology
This project involved creating a technology review and draft payer policy for an oncology product in early clinical phase trials. The results enabled the firm commissioning the report to move ahead with the acquisition of this product and subsequent advancement to later phase trials and NDA submission.
Novel drug/device combination
Our client is a biotech firm developing a novel drug/delivery device combination with significant potential to improve patient outcomes and reduce overall medical costs. Due to the innovative nature of this product, and the key role that payers will play in coverage and uptake Dr. Pezalla was engaged to hold discussions with potential investors and their consultants on the likely payment methodologies and payer response. The project entailed review of payer survey data, discussions with experts in the therapeutic area, and discussions with pharmacy and medical directors from representative payers.